Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer

The PI3K/AKT Pathway as a Target for Cancer Treatment

(2016) Ingrid A. Mayer et al.   Annual Review of Medicine

Drugging PI3K in cancer: refining targets and therapeutic strategies

(2015) Timothy A Yap et al.   CURRENT OPINION IN PHARMACOLOGY

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

Current treatment strategies for inhibiting mTOR in cancer

(2015) Francesca Chiarini et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus

(2014) Pengda Liu et al.   NATURE

Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer

(2013) Andrea Rocca et al.   EXPERT OPINION ON PHARMACOTHERAPY

The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice

(2013) Emma J. Haagensen et al.   PLoS One

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition

(2012) E J Haagensen et al.   BRITISH JOURNAL OF CANCER

Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma

(2012) C. K. Cheng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301

(2011) Huw D. Thomas et al.   EUROPEAN JOURNAL OF CANCER

CAL-101, a p110  selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

(2010) B. J. Lannutti et al.   BLOOD

Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors

(2010) Francesco Marchetti et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

PI3K and mTOR inhibitors—a new generation of targeted anticancer agents

(2009) Saskia Brachmann et al.   CURRENT OPINION IN CELL BIOLOGY

Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

(2009) Thomas S. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Common corruption of the mTOR signaling network in human tumors

(2009) S Menon et al.   ONCOGENE

Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms

(2009) A Satyanarayana et al.   ONCOGENE

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis

(2008) S. Maddika et al.   JOURNAL OF CELL SCIENCE

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE